State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Equities research analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) in a research report issued on Tuesday, MarketBeat ...
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which included a patient death from November in a patient who ...
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single Elevidys infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results